Eikon Therapeutics Seeks $908.2 Million Valuation in U.S. IPO
On Jan. 28, Eikon Therapeutics filed to pursue a U.S. initial public offering that would value the company at as much as $908.2 million and raise up to $317.7 million by selling 17.65 million shares at $16 to $18 apiece. The Millbrae, California-based drug developer is advancing a cancer pipeline led by EIK1001, being evaluated in combination with …